MetLife Investment Management LLC Has $485,000 Stock Position in Geron Corporation $GERN

MetLife Investment Management LLC trimmed its holdings in shares of Geron Corporation (NASDAQ:GERN) by 12.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 305,308 shares of the biopharmaceutical company’s stock after selling 42,611 shares during the period. MetLife Investment Management LLC’s holdings in Geron were worth $485,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Frisch Financial Group Inc. raised its position in Geron by 84.3% during the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 8,700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Geron by 3.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 384,411 shares of the biopharmaceutical company’s stock valued at $1,354,000 after buying an additional 11,652 shares during the period. GF Fund Management CO. LTD. acquired a new position in Geron during the fourth quarter valued at $45,000. Stifel Financial Corp raised its position in Geron by 29.9% during the fourth quarter. Stifel Financial Corp now owns 61,658 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 14,181 shares during the period. Finally, Nuveen Asset Management LLC raised its position in Geron by 0.7% during the fourth quarter. Nuveen Asset Management LLC now owns 1,994,807 shares of the biopharmaceutical company’s stock valued at $7,062,000 after buying an additional 14,657 shares during the period. 73.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group initiated coverage on Geron in a research report on Thursday, July 10th. They set a “sell” rating and a $1.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.19.

Geron Stock Up 1.4%

GERN opened at $1.40 on Monday. The firm has a market cap of $893.23 million, a P/E ratio of -10.77 and a beta of 0.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 7.87. The business has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.46. Geron Corporation has a twelve month low of $1.09 and a twelve month high of $4.83.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $49.04 million during the quarter, compared to analysts’ expectations of $47.30 million. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The company’s revenue was up 5455.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) earnings per share. Research analysts forecast that Geron Corporation will post -0.25 EPS for the current year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.